SCHEMBL13615284

SCHEMBL13615284

COc1ccc(OC)c(S(=O)(=O)Nc2ccc(C(C)(C)C)cc2C)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
NPSR1 Q6W5P4 2/20 0.60
MAPT P10636 2/20 0.58
BRD4 O60885 1/20 0.57
GAA P10253 3/20 0.57
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
TP53 P04637 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
KDM4E B2RXH2 1/20 0.57
POLB P06746 1/20 0.57
PKM P14618 1/20 0.57
HPGD P15428 1/20 0.57
ALOX15 P16050 1/20 0.57
CASP1 P29466 1/20 0.57
HTT P42858 1/20 0.57
HSD17B10 Q99714 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
WDR5 P61964 1/20 0.56
ALPL P05186 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16325536 0.87 FFAR4 (0.67) ALDH1A1NPSR1MAPTBRD4GAA
SCHEMBL13852850 0.84 BRD4 (0.56) BRD4GAAKMT2AMEN1SMN1; SMN2
SCHEMBL13615106 0.83 FFAR4 (0.72) ALDH1A1NPSR1GAAKMT2AMEN1
SCHEMBL13629390 0.82 ALDH1A1 (0.57) ALDH1A1NPSR1MAPTBRD4GAA
SCHEMBL5962567 0.81 ALDH1A1 (0.74) ALDH1A1NPSR1MAPTGAAKMT2A
SCHEMBL13852836 0.80 KEAP1 (0.64) ALDH1A1GAAKMT2AMEN1POLB
SCHEMBL13615080 0.76 ALDH1A1 (0.77) ALDH1A1NPSR1KMT2AMEN1TP53
SCHEMBL18530465 0.75 SMN1; SMN2 (0.79) ALDH1A1NPSR1GAAKMT2AMEN1
SCHEMBL12368219 0.74 ALDH1A1 (0.72) ALDH1A1NPSR1MAPTBRD4GAA
SCHEMBL7571491 0.74 NPC1 (0.67) ALDH1A1NPSR1MAPTGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2057/4885NPSR1 3787/4885MAPT 1454/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2121/4885NPSR1 4042/4885MAPT 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.